A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
A Two-Period, Randomized, Open-Label, Crossover Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75247
- Site #001
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Screening body weight 88 to 111 kg, inclusive;
- General good health with no clinically significant abnormalities that would affect ability to complete study as determined by medical history, physical examination, visual evaluation of the septum and turbinates to document baseline anatomy, electrocardiogram, clinical laboratory test results;
- Negative drug and alcohol testing;
- Negative pregnancy test for female subjects of childbearing potential.
Exclusion Criteria:
- Subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and who does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product;
- In the judgment of the Investigator, any clinically significant abnormality (such as septal perforations) or illness that would interfere with participation in this study as determined by medical history, physical examination (including visual exam of septum and turbinates), ECG, clinical laboratory results, or other screening safety tests;
- Any other condition and/or situation that causes the investigator to deem a subject unsuitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: diazepam nasal spray (AB)
Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses.
The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
|
diazepam nasal spray at two dose levels (DL).
One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Other Names:
|
|
Experimental: diazepam nasal spray (BA)
Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses.
The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
|
diazepam nasal spray at two dose levels (DL).
One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum measured plasma concentration (Cmax)
Time Frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
|
Area under the concentration curve from time 0 to the concentration at 24 hours (AUC0-24)
Time Frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
|
Area under the concentration curve from time 0 to infinity (AUCinf)
Time Frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
|
Apparent total body clearance of drug from plasma (CL/F)
Time Frame: within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
within 15 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with adverse events (AEs) including serious AEs
Time Frame: up to 21 days
|
up to 21 days
|
|
|
Change in focused nasal exam
Time Frame: within 30 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
within 30 minutes prior to dosing and at specified time points up to 24 hours post-dose
|
|
|
Taste change questionnaire
Time Frame: from 5 minutes up to 24 hours post-dose
|
If patient reports a change in taste associated with diazepam nasal spray, questionnaire to be completed by research staff.
|
from 5 minutes up to 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: David Squillacote, MD, Acorda Therapeutics
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Anticonvulsants
- Neuromuscular Agents
- Muscle Relaxants, Central
- Diazepam
Other Study ID Numbers
Other Study ID Numbers
- DZNS-PK-1034
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.